SiriusXM Holdings Inc. - Common Stock (SIRI)

Looking back on consumer discretionary - wireless, cable and satellite stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Si...

Investors may be paying up for reliability over growth.

The video game retailer is quiet, but three potential buyouts make sense for the small-box chain.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...

Sirius XM and SoFi have a lot to prove to win back investors' confidence.

Most consumer discretionary businesses succeed or fail based on the broader economy. Over the past six months, it seems like demand trends are working agains...

Ecopetrol (EC) Q3 2025 Earnings Call Transcript

Sirius XM's share price will need to rise 35% to achieve the target.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Satellite radio company Sirius XM may have become an overlooked value stock.

Over the past six months, Sirius XM’s shares (currently trading at $21.81) have posted a disappointing 8.4% loss, well below the S&P 500’s 3.1% gain. This ma...

Sirius XM provides subscription satellite radio and digital audio services to consumers, automakers, and commercial partners across the U.S.

These brand-name companies with high-octane dividend yields can pad the pocketbooks of patient investors.

Every investor wants to identify a stock that can produce life-changing returns.

The Trade Desk just delivered another disappointing earnings report.

As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary arterial hypertension (PAH), the company has recently captured Wall Street’s attention with a series of high-stakes maneuvers. Following a stellar Q4 2025 earnings report released [...]

Berkshire Hathaway's large stake in this music stock might pique the interest of ordinary investors.

SentinelOne and Sirius XM appear significantly mispriced relative to their long-term growth potential.

Investors in search of income might view this business as a compelling opportunity.

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

These three companies you know are trading for less than 10 times forward earnings.